News Release

Inotek Pharmaceuticals Presents Preclinical Data on Trabodenoson at the Association for Research in Vision and Ophthalmology (ARVO) 2017 Annual Meeting

Printer Friendly Version View printer-friendly version

LEXINGTON, Mass.--(BUSINESS WIRE)--May 8, 2017-- Inotek Pharmaceuticals Corporation (NASDAQ: ITEK), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for ocular diseases, today announced the presentation of preclinical data of trabodenoson at the Association for Research in Vision and Ophthalmology (ARVO) 2017 Annual Meeting in Baltimore, MD. The Company will present five poster presentations at the meeting based on preclinical research of trabodenoson as a monotherapy and as a combination with latanoprost. Two of the five posters specifically focus on the neuroprotective potential of the ocular delivery of trabodenoson in preclinical models.

“We are excited to share some intriguing preclinical data of trabodenoson this week at ARVO 2017,” said Rudolf Baumgartner, MD, Executive Vice President and Chief Medical Officer of Inotek. “Notably, data supporting trabodenoson’s neuroprotective activity in the back of the eye demonstrates the potential to preserve the function and number of retinal ganglion cells in non-arteritic anterior ischemic optic neuropathy (NAION). NAION is an ocular condition that causes sudden vision loss due to a lack of blood flow to the optic nerve. Inotek will continue our preclinical research of trabodenoson in optic nerve diseases and conditions in the back of the eye, such as neuroenhancement.”

“Inotek’s preclinical results show potential for treating neuro-ophthalmic diseases and other areas of unmet medical need,” said Leonard A. Levin, MD, PhD, Professor and Chair of Ophthalmology, McGill University and Professor of Ophthalmology and Visual Sciences, University of Wisconsin. “We need treatment options that help people with irreversibly blinding diseases. Neuroenhancement and neuroprotection are key tools needed to treat neuro-ophthalmic conditions. Neuroenhancement attempts to keep cells functioning better while neuroprotection attempts to keep cells alive; both strategies are being studied by Inotek.”

The trabodenoson neuroprotective poster presentation details are as follows:

  • Neuroprotective Efficacy of Topical Ocular Delivery of Trabodenoson in a Rodent Model of Anterior Ischemic Optic Neuropathy
    Authors: C Rich, D Albers, R Fawcett, Y Guo, Z Mehrabyan, R Baumgartner, and S Bernstein
    Date: Monday, May 8, 2017
    Time: 11:00am to 12:45pm ET
  • Neuroprotective Evaluation of Topically Delivered Trabodenoson in an Acute Ischemic Rodent Model
    Authors: J Gow, C Crosson, D Albers, C Rich, and R Baumgartner
    Date: Thursday, May 11, 2017
    Time: 11:30am to 1:15pm ET

Additionally, Inotek will also present the below:

  • Intraocular Pressure Lowering Following Topical (Ocular) Delivery of Trabodenoson: Effects of Preservative and Age in Living Mice
    Authors: D Albers, G Li, W McVicar, and W D Stamer
    Date: Monday, May 8, 2017
    Time: 3:45pm to 5:30pm ET
  • Quantitative Ocular and Whole-Body Autoradiography Following a Single Topical Ocular Administration of Trabodenoson to Rabbits
    Authors: C Murray, A Brockman, D Albers, and W McVicar
    Date: Wednesday, May 10, 2017
    Time: 11:00am to 12:45pm ET
  • Safety and Tolerability of Trabodenoson and Latanoprost in Dogs Following a 39 Week Ocular (Topical) Instillation
    Authors: A Brockman, D Albers, and W McVicar
    Date: Thursday, May 11, 2017
    Time: 8:30am to 10:15am ET

About Inotek Pharmaceuticals Corporation

Inotek Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for glaucoma and other eye diseases. The Company’s lead product candidate, trabodenoson, is a first-in-class selective adenosine mimetic currently in Phase 3 development. Trabodenoson was developed in Inotek’s laboratories and is designed to restore the eye’s natural pressure control mechanism. Additionally, the Company is evaluating the potential for selective adenosine mimetics to address optic neuropathies and other degenerative retinal diseases. For more information, please visit The inclusion of our website address here and elsewhere in this press release does not include or incorporate by reference the information on our website into this press release.

Forward-Looking Statements

This press release contains forward-looking statements, which are subject to substantial risks, uncertainties and assumptions. You should not place reliance on these statements which often include words such as "believe," "expect," "anticipate," "intend," "plan," "estimate," "seek," "will," "may" or similar expressions. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee such outcomes. Accordingly, you should not place undue reliance on these forward-looking statements. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Source: Inotek Pharmaceuticals Corporation

Inotek Contact:
Claudine Prowse, PhD, 781-552-4305
Vice President, Corporate Development and IRO